


Seminar Series - 2017

When: Monday 28th AUGUST @ 12:00 pm

Where: Rand Theatre, Level 8, Medical Building



*“Accelerating drug discovery
through tight integration of expert
molecular design and predictive
scoring”*

Dr Fiona McRobb
Schrödinger Pty Ltd, NY, USA

Fiona McRobb graduated from Monash University with a Bachelor of Medicinal Chemistry (Hons), for which she received the Bachelor of Medicinal Chemistry Gold Medal. She completed her Ph.D. in 2012 at the Monash Institute of Pharmaceutical Sciences (MIPS), where she worked on the molecular modelling of G protein-coupled receptors and the organic synthesis of bivalent ligands of clozapine.

Fiona went on to complete a postdoctoral fellowship with Prof. Ruben Abagyan at the University of California, San Diego. During this time she worked on a range of projects including the molecular modelling of allosteric enhancers of GPCRs, the determination of the ligand binding site conservation of toxicity targets in five aquatic species, and the *in silico* identification and pharmacological evaluation of novel endocrine disrupting chemicals.

In 2014, Fiona joined Schrödinger, a science and technology leader in developing chemical simulation software aimed at transforming drug discovery research, in New York City. Through her role as an Applications Scientist, she applied Schrödinger's computational chemistry software to address challenging problems in drug discovery. Fiona currently holds the role of Associate Principal Scientist within the Drug Discovery Group at Schrödinger.

Schrödinger:

Schrödinger is a science and technology leader in developing chemical simulation software aimed at transforming drug discovery research. The company's products are used by nearly all the top pharmaceutical companies worldwide. Schrödinger also engages in drug discovery collaborations utilizing its best-in-class software solutions for modelling small molecules and protein therapeutics.